Biovail Prices US$400 Million 7.875% Senior Subordinated Notes Due 2010.Business Editors and Health/Medical Writers TORONTO--(BW HealthWire)--March 26, 2002 Biovail Corporation (NYSE NYSE See: New York Stock Exchange :BVF)(TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :BVF) announced today that it has entered into an Underwriting Agreement for a public offering of US$400 million of 7.875% senior subordinated notes due 2010. The senior subordinated notes will be offered to the public at a price of 99.27% of their aggregate principal amount. The offering is being made in the United States and Canada under Biovail's shelf prospectus filed with U.S. and Canadian securities authorities in November 2001. Biovail will use the net proceeds from the offering to repay existing debt and for general corporate purposes. The Sole Bookrunning Manager is UBS Warburg. The co-lead managers are Credit Suisse First Boston Credit Suisse First Boston was originally the trading name of the Financière Crédit Suisse-First Boston, a London-based 50-50 investment banking joint venture formed in 1978 between the First Boston Corporation and Credit Suisse. , JPMorgan, Morgan Stanley and Scotia Capital and the co-managers are BMO Nesbitt Burns  This article or section is written like an .Please help [ rewrite this article] from a neutral point of view. Mark blatant advertising for , using . and RBC Capital Markets RBC Capital Markets is the corporate and investment banking division of Royal Bank of Canada ("RBC"). Broker dealers Depending on the jurisdiction, the division uses different broker dealer subsidiaries of RBC:
This communication shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any such jurisdiction. Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, sale and promotion of pharmaceutical products utilizing advanced drug delivery technologies. "Safe Harbor" statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. To the extent any statements made in this release contain information that is not historical, these statements are essentially forward looking and are subject to risks and uncertainties, including the difficulty of predicting FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, the regulatory environment, the outcome of litigation, fluctuations in operating results and other risks detailed from time to time in the company's filings with the United States Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion